title: Oral lichen planus and intake of drugs metabolized by polymorphic cytochrome P450 enzymes.
abstract: OBJECTIVE
  To study if patients with oral lichen planus (OLP) had a medication profile different from that of a control group without oral mucosal lesions. It was hypothesized that OLP lesions might result from poor drug metabolism (PM) because of genetic variation of the major cytochrome P450-enzymes (CYPs with a PM-risk).
  
  
  METHODS
  Dental records of 172 OLP patients were reviewed in this cross-sectional study and 152 sex- and age-matched subjects served as controls. The measures for the drug profiles were medicine type (ATC-code), mono- and polypharmacy, CYP-enzyme metabolism pattern, and medicine with a potential to induce lichenoid drug eruptions.
  
  
  RESULTS
  Fifty per cent of the OLP patients consumed daily medications as compared with 59% of the controls. The OLP patients more frequently consumed medicines metabolized by CYPs with a PM-risk (P = 0.03). Furthermore, they consumed more medicine with an inhibitory effect on one or more CYPs than the controls (P = 0.01).
  
  
  CONCLUSIONS
  Confounders like sex, age, systemic diseases, drug distribution into the therapeutic classes, and polypharmacy were similar in the two groups; but the OLP patients consumed more drugs metabolized by CYPs with a PM-risk. The results argue for further investigation of associations between OLP, medication intake and the CYP-enzyme metabolic pathways.
authors.affiliation: Department of Oral Medicine, Clinical Oral Physiology, Oral Pathology & Anatomy, School of Dentistry, Faculty of Health Sciences, University of Copenhagen, Denmark. ckr@odont.ku.dk
authors.forename: C
authors.initials: C
authors.lastname: Kragelund
authors.forename: C E
authors.initials: CE
authors.lastname: Thomsen
authors.forename: A
authors.initials: A
authors.lastname: Bardow
authors.forename: A M
authors.initials: AM
authors.lastname: Pedersen
authors.forename: B
authors.initials: B
authors.lastname: Nauntofte
authors.forename: J
authors.initials: J
authors.lastname: Reibel
authors.forename: L A
authors.initials: LA
authors.lastname: Torpet
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D016022:Case-Control Studies; D003430:Cross-Sectional Studies; D065607:Cytochrome P-450 Enzyme Inhibitors; D003577:Cytochrome P-450 Enzyme System / Q000235:genetics / Q000378:metabolism*; D004194:Disease; D004358:Drug Therapy; D005260:Female; D015971:Gene Expression Regulation, Enzymologic / Q000235:genetics; D014644:Genetic Variation / Q000235:genetics; D006801:Humans; D017676:Lichen Planus, Oral / Q000139:chemically induced*; D008297:Male; D008875:Middle Aged; D004364:Pharmaceutical Preparations / Q000145:classification / Q000378:metabolism; D019338:Polypharmacy; D012737:Sex Factors
chemical_list: D065607:Cytochrome P-450 Enzyme Inhibitors; D004364:Pharmaceutical Preparations; D003577:Cytochrome P-450 Enzyme System